Awareness of, and Compliance with, Domperidone Revised Labeling After a Risk-Minimization Activity in Europe

ConclusionsThe survey findings documented that most physicians in all five countries were aware of the main aspects of the revised labeling. Results of the DUS were inconclusive regarding the effect of the RMM and compliance with the revised labeling for all countries except France.

http://link.springer.com/10.1007/s40261-019-00831-3

Source: Clinical Drug Investigation - July 18, 2019 Category: Drugs & Pharmacology Source Type: research